

ORIGINAL ARTICLE

Rationale, design and methodology of the RAMSES Study: ReAI-life Multicenter Survey Evaluating Stroke Prevention Strategies

Türkiye’de nonvalvuler atriyum fibrilasyonlu hastalarda inme önleme stratejilerinin değerlendirilmesi RAMSES (ReAI-life Multicenter Survey Evaluating Stroke Prevention Strategies) çalışması

Özcan Başaran, M.D., Volkan Doğan, M.D., Kadriye Memic Sancar, M.D., İbrahim Altun, M.D., Kadir Uğur Mert, M.D., Gurbet Özge Mert, M.D., Nesrin Filiz Başaran, M.D.,# Edip Güvenç Çekiç, M.D.,# Cevat Kıрма, M.D.,* Murat Biteker, M.D. on behalf of the RAMSES investigators

Department of Cardiology, Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey

#Department of Pharmacology, Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey

*Department of Cardiology, Kartal Koşuyolu Heart Training and Research Hospital, İstanbul, Turkey

ABSTRACT

Objective: Atrial fibrillation is the most common arrhythmia and is associated with a five- fold increased risk of thromboembolic events. Vitamin K antagonists (VKAs) have been the mainstay of oral anticoagulant prophylaxis and the data on stroke prevention strategies are limited to VKA era. The purpose of this study is to evaluate the use of VKA, non-Vitamin K antagonist oral anticoagulants (NOAC), and antiplatelet agents in patients with non-valvular atrial fibrillation (NVAF).

Methods: The ReAI-life Multicenter Survey Evaluating Stroke prevention strategies in Turkey (RAMSES) is an observational, multicenter, prospective study of patients with NVAF. The study targeted enrollment of 7835 patients from 68 sites in Turkey. All the data will be collected at one point in time and current clinical practice will be evaluated. (ClinicalTrials.gov number NCT02344901).

Results: Baseline characteristics of patients, antithrombotic therapies, transition to NOACs and rate/rhythm control strategies will be evaluated.

Conclusion: The RAMSES registry will be the largest study in Turkish NVAF patients. The study will provide insights into real-world problems and anticoagulant treatment in patients with NVAF.

Atrial fibrillation (AF), classified as nonvalvular (NVAF) in the absence of rheumatic mitral stenosis or valvular prosthesis, is the most common arrhythmia, with an estimated prevalence of 1.5–2%.^[1]

ÖZET

Amaç: Atriyum fibrilasyonu (AF) en sık saptanan aritmi olup tromboembolik olay oranında 5 kat artışla ilişkilidir. Non-valvüler atriyum fibrilasyonunda (NVAF) inme önleme stratejileri ile ilgili olan bilgilerimiz daha çok vitamin K antagonisti (VKA) olan ilaçlar hakkındadır. Bu çalışma NVAF olan hastalarda VKA, non-vitamin K antagonisti oral antikoagülan (NOAK) ve antiagregan tedavilerin kullanımını değerlendirmek için tasarlanmıştır.

Yöntemler: RAMSES (ReAI-life Multicenter Survey Evaluating Stroke prevention strategies in Turkey) çalışması NVAF’li hastalarda gözlemsel, çok merkezli ve ileriye dönük bir çalışma olarak tasarlandı. Çalışmaya Türkiye’de 68 merkezden 7835 hasta alınması planlandı. Hastalarla ilgili tüm verilerin tek bir ziyarette alınması ve klinik yaklaşımların değerlendirilmesi planlandı. (ClinicalTrials.gov numarası NCT02344901).

Bulgular: Hastaların bazal demografik verileri, kullanmakta oldukları antitrombotik tedavileri, NOAK’lara geçiş ve hız/ritim kontrol stratejilerinin değerlendirilmesi planlandı.

Sonuç: RAMSES kayıt çalışması NVAF’li hastalar hakkında Türkiye’de yapılmış en büyük çalışma olacaktır. Bu çalışmanın NVAF’li hastalarda antikoagülan tedavileri ve sorunlarla ilgili gerçek hayattan veriler sağlaması beklenmektedir.

AF is associated with a 5-fold higher risk of arterial thromboembolic events.^[2] The risk of death is also doubled, and AF-related stroke is more severe and causes greater disability than stroke in patients with-

Received: September 13, 2015 Accepted: October 28, 2015

Correspondence: Dr. Özcan Başaran. Muğla Sıtkı Koçman Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Muğla, Turkey.

Tel: +90 252 - 214 13 26 e-mail: basaran_ozcan@yahoo.com

© 2016 Turkish Society of Cardiology



out AF.^[3] To prevent stroke in patients with NVAf, antithrombotic treatments are employed with oral anticoagulants (OAC) such as vitamin K antagonists (VKA) and, in a number of

Abbreviations:

AF	Atrial fibrillation
EORP-AF	EURObservational Research Programme Atrial Fibrillation
INR	International normalized ratio
NOACs	Non-vitamin K antagonist oral anticoagulants
NVAf	Nonvalvular atrial fibrillation
OAC	Oral anticoagulants
TTR	Time in therapeutic range
VKA	Vitamin K antagonists

circumstances, with antiplatelet agents. Oral anticoagulation with dose-adjusted VKA has resulted in a 64% risk reduction of stroke rates.⁴ However, reduction in the relative risk of stroke in patients with AF treated with antiplatelets compared with placebo or no treatment is only 19%.^[4] Current guidelines for the management of AF recommend OAC therapy for patients who are at moderate to high risk for thromboembolic events, and no antithrombotic or antiplatelet therapy is recommended for patients who are at low risk.^[5,6] Although VKAs (mainly warfarin) are highly effective in reducing the risk of stroke, and have been the sole choice for stroke prevention during the last 50 years, their use is limited for a number of reasons: narrow therapeutic range, drug and food interactions, need for monitoring, and risk of bleeding. Recently, non-vitamin K antagonist oral anticoagulants (NOACs) have been marketed for this indication. These relatively new agents have been evaluated in large randomized multicenter clinical trials and shown to be at least as effective as warfarin with a better safety profile.^[7-9] However, these trials may not reflect real-world settings, due to inclusion of selected populations without severe comorbidities.

Although large observational cohort studies have been performed to overcome this limitation, these studies mainly focused on VKA therapy.^[10,11] The introduction of NOACs to clinical practice might have led to a change in physicians' approach to NVAf patients.

The aims of this study are: (1) to demonstrate the current status of the clinical background of patients with NVAf, (2) to determine standard clinical practice on stroke prevention, and (3) to analyze the appropriateness of anticoagulant therapies in patients with NVAf in a large multicenter nationwide trial.

METHODS

Study design

The RAMSES study (ClinicalTrials.gov identifier NCT02344901) is planned as a national multicenter cross-sectional registry. Sample selection and loss to follow-up are common concerns in longitudinal studies. To overcome this bias, this study has been designed as a cross-sectional study to allow inclusion of all consecutive patients with NVAf.

Setting

The study will be conducted in outpatient cardiology clinics, and all data collected in a single visit. We planned to enroll a total number of 7835 patients after contacting 68 sites, which are all expected to participate. To ensure inclusion of adequate geographic diversity, it is planned to enroll a proportional number of patients to the population of every region. State, university, education and research, and private hospitals are included to represent all patients treated within the different health care settings. The study was initiated in February 2015 and the last patient was enrolled in May 2015.

Study population

All consecutive patients admitted to the outpatient cardiology clinics with electrocardiographically confirmed NVAf of age ≥ 18 years will be enrolled. Although the definition of NVAf is controversial, valvular AF is defined as AF related to rheumatic valvular disease (predominantly mitral stenosis), or prosthetic heart valves in the RAMSES study. The RAMSES trial excluded patients with mitral stenosis, or a mechanical prosthetic heart valve.

Outcomes

Patient characteristics and demographics, including geographical diversity, of the patient characteristics and OAC use will be described. Guideline-based use of anticoagulation in eligible patients and reasons for not being on OAC therapy will be analyzed. The primary outcome of the RAMSES study is the appropriateness of stroke prevention strategies in patients with NVAf. Secondary outcome measures include time in therapeutic range (TTR) for patients on warfarin, CHA₂DS₂VASc (congestive heart failure or left ventricular dysfunction, hypertension, age ≥ 75 years, diabetes, thromboembolism or stroke history, vascular

disease, age 65–74 years, and sex) and HAS-BLED (hypertension, renal or liver failure, stroke history, bleeding history, labile international normalized ratio, age >65 years, drugs, or alcohol) scores and their relation with OAC use. The impact of coronary artery disease, congestive heart failure and renal failure on OAC therapy will be evaluated. Particular interest will be devoted to the lower dosages of NOACs and their consistent use with recommendations.

Data collection

Patient characteristics will be questioned by survey. Demographic data including age, sex, body weight, smoking status, pulmonary disease, level of education, place of residence (rural or urban), and type of AF will be noted. Stroke-associated risk factors such as coronary artery disease, hypertension, diabetes mellitus, previous stroke, congestive heart failure, and vascular disease (prior myocardial infarction, peripheral artery disease, or aortic plaque) will also be questioned. Subsequently patients' ongoing pharmacologic treatment for stroke prevention (antiplatelet, anticoagulant, or none) and antiarrhythmic drug therapy will be questioned. Hemorrhagic events related to the current therapy, international normalized ratio (INR), and creatinine levels will be noted. For patients on VKA therapy, time in therapeutic range (TTR) will be calculated by two methods (1) cross-sectional: The ratio of in-range (2-3) INRs to all INRs at a specific time and (2) traditional: The ratio of in-range (2-3) INRs to all INRs of a patient. Renal functions will be estimated using creatinine clearance calculated by the Cockcroft-Gault formula. Inappropriate use of OACs will be assessed according to current guidelines. Major bleeding is defined according to International Society on Thrombosis and Haemostasis criteria^[12] and minor bleeding is defined as a non-major bleeding. Lastly, any type of valvular pathology and the reason for not being on OAC therapy will be evaluated.

The study was approved by local ethics committee (Mugla Sitki Kocman University). The enrollment of patients was started in February 2014. All the participating institutions will enroll all consecutive patients with NVAF under regular outpatient care. Written informed consent will be obtained from patients.

Sample size

The goal of enrolling 7835 patients was determined after contacting 68 invited sites. This will allow for

capture of a large, representative number of patients with AF in Turkey. In addition, it was planned to enroll proportional numbers of patients according to the seven regions of Turkey.

Statistical analyses

Continuous variables will be summarized by median and interquartile range or mean±standard deviation (SD). Categorical variables will be expressed as frequencies and percentages. Univariate analysis will be performed for continuous variables and chi-square or Fisher exact test will be applied for categorical variables. Correlation between variables will be assessed by Pearson or Spearman test. A p value of <0.05 will be considered significant.

DISCUSSION

The RAMSES study will be the largest study among Turkish patients with NVAF, and one of the largest in the world. The findings of this study will provide important real world evidence, as well as potentially providing a better understanding of the burden of NVAF and the variability in disease management in individual units. The design of the study will allow an evaluation of both newly-diagnosed and prevalent patients with NVAF in a non-randomized, non-selected population. Patients who are at risk for thromboembolic events will be identified. Underuse of oral anticoagulation in patients at elevated risk, barriers to prescribing antithrombotic therapy, and overuse in those at low risk will be researched. The study will also provide information regarding NOAC use in a real-life, large cohort of patients in Turkey for the first time. A snapshot of the characteristics and antithrombotic therapies of NVAF patients will guide physicians in future treatment decisions.

Contemporary ongoing large-scale registries provide data on management and prevention of thromboembolism in patients with AF.^[13–16] The design of these and previous studies is shown in Table 1. The registry data regarding stroke prevention strategies in NVAF patients is limited to VKAs and antiplatelet agents. The preliminary results of “The Global Anticoagulant Registry in the FIELD (GARFIELD)”, “A Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF)”, and “EURObservational Research Programme Atrial Fibrillation (EORP-AF)” have shown

Table 1. Comparison of study designs of observational studies

	GLORIA-AF	GARFIELD	ORBIT-AF II	EORP-AF	AFTER	RAMSES
Population	Inpatient and outpatient, newly diagnosed, at risk for stroke	Inpatient and outpatient, newly diagnosed, at risk for stroke	Outpatient, newly diagnosed	Inpatient and outpatient	Outpatient	Outpatient
Enrollment	56.000	55.000	15.000	3119	2242	7835 (intended)
Follow-up	3 years	2 years	2 years	3 years	Cross-sectional	Cross-sectional
Study period	2011-ongoing	2009- ongoing	2013-ongoing	2012-ongoing	2012	2015
No of countries	50 (5 regions)	50	1 (USA)	9 (Europe)	1 (Turkey)	1 (Turkey)
No of sites	2200	1000	300	N/A	17	68 (intended)
OAC studied	W, D, R, A	W, D, R, A	W, D, R, A	W, D, R, A	W	W, D, R, A

GLORIA-AF: Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation; GARFIELD: Global Anticoagulant Registry in the FIELD; ORBIT-AF II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II; EORP-AF: EURObservational Research Programme Atrial Fibrillation; AFTER: The atrial fibrillation in Turkey: Epidemiologic Registry, W: Warfarin; D: Dabigatran; R: Rivaroxaban; A: Apixaban.

NOAC use in a minority of patients. These large scale registries were undertaken at the beginning of the NOAC era, and follow-up data will provide information regarding transition from VKAs to NOACs. However, our study will provide current data showing recent problems in the management of AF.

The utilization of OAC therapy among patients with AF has gradually increased. The overall use of OAC therapy was 70% in the EuroHeart survey and AFNET registries, and rose to 80% in the EORP-AF registry.^[10,16,17] However, a large multicenter study from our country found that only 40% of patients with NVAf were anticoagulated (VKA) and TTR was 39% for these patients. In addition, antiplatelet therapy was widely used (about two-third of patients were receiving at least one antiplatelet drug), while 17% of patients were not receiving any antithrombotic therapy.^[18] VKA-associated problems and low TTR might be reasons for undercoagulation in our country, as the main reason of not being anticoagulated was physician neglect.^[19] This study will shed light on whether these reservations are ongoing and if they lead to a transition from VKA to NOAC.

Our study will provide data how emerging therapies in the OAC era are applied in daily practice, and reveal adherence among physicians to current practice guidelines.

Limitations

The RAMSES study is a limited cross-sectional survey that will provide a snapshot of the disease. Therefore, it will not be able to observe the course of the disease and information regarding stroke and mortality data will be limited. Another limitation is dependence on the quality of medical records. Lastly, the coverage of the study is limited to outpatient cardiology clinics.

Conclusion

Awareness of AF and AF-related stroke has increased and the drug of choice is OAC. This study is designed to evaluate current clinical practice regarding stroke prevention strategies in patients with NVAf. The results will help to generate hypotheses for the improvement of prevention strategies and for better understanding the course of the disease.

Collaborators

Osman Beton, MD, Assistant Prof¹, Mehmet Tekinalp, MD², Ahmet Çağrı Aykan, MD³, Ezgi Kalaycıoğlu, MD³, İsmail Bolat, MD⁴, Onur Taşar, MD⁵, Özgen Şafak, MD⁶, Macit Kalçık, MD⁷, Mehmet Yaman, MD⁸, Sinan İnci, MD⁹, Bernas Altıntaş, MD¹⁰, Sedat Kalkan, MD¹¹, Fatma Özpamuk Karadeniz, MD¹², Ahmet İlker Tekkesin, MD¹³, Yasin Çakıllı, MD¹⁴, Ceyhan Türkkkan, MD¹³, Mehmet Hamidi, MD¹⁵, Vahit Demir, MD¹⁶, Mustafa Ozan Gürsoy, MD¹⁷, Müjgan Tek Öztürk, MD¹⁸, Gökhan Aksan, MD¹⁹,

Sabri Seyis, MD²⁰, Mehmet Ballı, MD²¹, Mehmet Hayri ALICI, MD²², Serdar Bozyel, MD²³, Feyza Çalık, MD²⁴, Oğuz Karaca, MD, Assist. Prof²⁵, Füsün Helvacı, MD¹⁹, Kadriye Akay, MD²⁶, Yiğit Çanga, MD²⁷, Savaş Çelebi, MD²⁸, Emine Altuntas, MD²⁹, Mehmet Aytürk, MD¹⁸, Hacı Murat Güneş, MD, Assistant Prof²⁵, Tahir Bezgin, MD³⁰, Aytekin Aksakal, MD⁸, Beytullah Çakal, MD, Assistant Prof²⁵, Ayşe Çolak, MD³¹, Özgür Kaplan, MD³², Adem Tatlısu, MD³³, Gökhan Gözübüyük, MD³², Selami Demirelli, MD³⁴, Adnan Kaya, MD³⁵, İbrahim Rencüzoğulları, MD, Assist Prof³⁶, Zübeyde Bayram, MD²⁷, Zeki Şimşek, MD²⁷, Murat Civan, MD³⁷, Ulaankhu Batgharel, MD³⁸, Ali Ekber Ata, MD³⁹, Gökhan Göl, MD⁴⁰, Aleks Değirmencioglu, MD⁴¹, Özkan Candan, MD⁴², Özlem Özcan Çelebi, MD⁴³, Cem Doğan, MD³², Fethi Yavuz, MD⁴⁴, Şeref Ulucan, MD, Assistant Prof⁴⁵, Arif Arısoy, MD, Assist Prof⁴⁶, Bingül Dilekçi Şahin, MD³⁴, Emrah Ermiş, MD³⁴, Serkan Gökaslan, MD⁴⁷, İdris Pektaş, MD⁴⁸, Aslı Tanındı, MD, Assist Prof⁴⁹, Kamuran Tekin, MD⁵⁰, Ekrem Bilal Karaayvaz, MD⁵¹, Mevlut Koc, MD, Assoc. Prof⁵², Durmus Yıldırım Şahin, MD, Assoc. Prof⁵², Tolga Çimen, MD⁵³, Tolga Sinan Güvenç, MD¹³, Nihat Pekel, MD, Assist Prof⁵⁴, Kerem Temel, MD⁵⁵, Vehip Keskin, MD⁵⁶, Mustafa Özcan Soylu, MD, Associate Prof⁵⁷, Fatih Akın, MD, Assist Prof⁵⁷

Affiliations

¹Sivas Cumhuriyet University, Faculty of Medicine, Department of Cardiology, ²Kahramanmaraş Necip Fazıl State Hospital, Department of Cardiology, ³Trabzon Ahi Evren Chest Cardiovascular Surgery Education and Research Hospital, Department of Cardiology, ⁴Fethiye State Hospital, Department of Cardiology, ⁵Elazığ Education and Research Hospital, Department of Cardiology, ⁶Burdur State Hospital, Department of Cardiology, ⁷İskilip Atıf Hoca State Hospital, Department of Cardiology, ⁸Samsun Education and Research Hospital, Department of Cardiology, ⁹Aksaray State Hospital, Department of Cardiology, ¹⁰Diyarbakır Gazi Yaşargil Education and Research Hospital, Department of Cardiology, ¹¹Gönen State Hospital, Department of Cardiology, ¹²Şanlıurfa Balıklıgöl State Hospital, Department of Cardiology, ¹³Siyami Ersek Heart Education and Research Hospital, Department of Cardiology, ¹⁴Tuzla State Hospital, Department of Cardiology, ¹⁵Bandırma State Hospital, Department of Cardiology, ¹⁶Yozgat State Hospital, Department of Cardiology, ¹⁷Gaziantep State Hospital, Department of Cardiology, ¹⁸Ankara Keçiören Education and Research Hospital, Department of Cardiology, ¹⁹Şişli Hamidiye Etfal Education and Research Hospital, Department of Cardiology, ²⁰Mersin Private Dogus Hospital, Department of Cardiology, ²¹Mersin Toros State Hospital, Department of Cardiology, ²²Gaziantep 25 Aralık State Hospital, Department of Cardiology, ²³Kocaeli Derince Education and Research Hospital, Department of Cardiology, ²⁴Mersin State Hospital, Department of Cardiology, ²⁵İstanbul Medipol

University Faculty of Medicine, Department of Cardiology, ²⁶Kocaeli State Hospital, Department of Cardiology, ²⁷Kartal Yavuz Selim State Hospital, Department of Cardiology, ²⁸TOBB ETÜ Hospital, Department of Cardiology, ²⁹Bingöl State Hospital, Department of Cardiology, ³⁰Gebeze Fatih State Hospital, Department of Cardiology, ³¹Mut State Hospital, Department of Cardiology, ³²Malatya State Hospital, Department of Cardiology, ³³Sivas Numune State Hospital, Department of Cardiology, ³⁴Erzurum Bölge Education and Research Hospital, Department of Cardiology, ³⁵Suruç State Hospital, Department of Cardiology, ³⁶Kafkas University Faculty of Medicine, Department of Cardiology, ³⁷İstanbul Private Liv Hospital, Department of Cardiology, ³⁸Acıbadem Private Hospital, Department of Cardiology, ³⁹Samsun Medikal Park Hospital, Department of Cardiology, ⁴⁰Süreyyapaşa Education and Research Hospital, Department of Cardiology, ⁴¹İstanbul Acıbadem University Faculty of Medicine, Department of Cardiology, ⁴²Uşak State Hospital, Department of Cardiology, ⁴³Private Medicana International Ankara Hospital, Department of Cardiology, ⁴⁴Dr. Ersin Arslan State Hospital, Department of Cardiology, ⁴⁵Mevlana University Faculty of Medicine, Department of Cardiology, ⁴⁶Gaziosmanpaşa University Faculty of Medicine, Department of Cardiology, ⁴⁷İstanbul Haydarpaşa Numune Education and Research Hospital, Department of Cardiology, ⁴⁸Mersin University Faculty of Medicine, Department of Cardiology, ⁴⁹Ufuk University Faculty of Medicine, Department of Cardiology, ⁵⁰Batman Bölge State Hospital, Department of Cardiology, ⁵¹Bağcılar Education and Research Hospital, Department of Cardiology, ⁵²Adana Numune Education and Research Hospital, Department of Cardiology, ⁵³Dışkapı Yıldırım Beyazıt Education and Research Hospital, Department of Cardiology, ⁵⁴İzmir Medikal Park Hospital, Department of Cardiology, ⁵⁵Acıbadem Eskişehir Hospital, Department of Cardiology, ⁵⁶Muğla Private Cardiology Clinic, ⁵⁷Muğla Sıtkı Koçman University Faculty of Medicine, Department of Cardiology

Conflict-of-interest issues regarding the authorship or article: None declared

REFERENCES

1. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. *Medical Clinics of North America* 2008;92:17–40. [CrossRef](#)
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 1991;22:983–8. [CrossRef](#)
3. Banerjee A, Marin F, Lip GY. A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. *Stroke* 2011;42:3316–22.
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonval-

- vular atrial fibrillation. *Ann Intern Med* 2007;146:857–67.
5. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J* 2012;33:2719–47. [CrossRef](#)
 6. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation* 2014;130:2071–104.
 7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139–51. [CrossRef](#)
 8. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;365:883–91. [CrossRef](#)
 9. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;365:981–92. [CrossRef](#)
 10. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. *Eur Heart J* 2005;26:2422–34. [CrossRef](#)
 11. Cullen MW, Kim S, Piccini JP Sr, Ansell JE, Fonarow GC, Hylek EM, et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. *Circ Cardiovasc Qual Outcomes* 2013;6:461–9. [CrossRef](#)
 12. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. *J Thromb Haemost* 2005;3:692–4.
 13. Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. *Am Heart J* 2014;167:329–34. [CrossRef](#)
 14. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). *Am Heart J* 2012;163:13–9. [CrossRef](#)
 15. Steinberg BA, Blanco RG, Ollis D, Kim S, Holmes DN, Kowey PR, et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. *Am Heart J* 2014;168:160–7. [CrossRef](#)
 16. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. *Europace* 2014;16:308–19. [CrossRef](#)
 17. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, et al. The Registry of the German Competence NETWORK on Atrial Fibrillation: patient characteristics and initial management. *Europace* 2009;11:423–34. [CrossRef](#)
 18. Kaya H, Ertas F, Koroglu B, Vatan B, Cagliyan CE, Gedik S, et al. Predictors of anticoagulant treatment in patients with nonvalvular atrial fibrillation: results from atrial fibrillation in Turkey: epidemiologic registry. *Clin Appl Thromb Hemost* 2015;21:144–8. [CrossRef](#)
 19. Ertas F, Eren NK, Kaya H, Aribas A, Acar G, Kanadası M, et al. The atrial fibrillation in Turkey: Epidemiologic Registry (AFTER). *Cardiol J* 2013;20:447–52. [CrossRef](#)

Keywords: Atrial fibrillation; oral anticoagulant; risk scores; stroke; Turkey.

Anahtar sözcükler: Atrial fibrilasyon; oral antikoagulan; risk skorları; inme; Turkey.